Floatz logo

Olutasidenib

IDH1 R132H

Rigel PharmaceuticalsSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the IDH1 R132H cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Olutasidenib is also rated in:

gliomaDormant
BBB
Indicative ·
72 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →